BusinessHemispherx Biopharma Exploring Possible Research Programs in Zika Virus Modeled on a Prior Alferon® N Clinical Trial on Closely Related Flavivirus (West Nile)By Nasdaq OMXFeb 9, 2016, 1:30 PM UTC
BusinessHemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder ValueBy Nasdaq OMXFeb 3, 2016, 1:30 PM UTC
BusinessEarth Science Tech Supported Positive Scientific Research Studies and Customer Feedback on its Phytocannabinoid-CBD (Cannabidiol) Rich Hemp Oil Prompts Company to Launch Non-Profit Phytocannabinoid-CBD Research FoundationBy Nasdaq OMXFeb 3, 2016, 12:45 PM UTC
BusinessAREVA Med’s Second Production Facility on Schedule to Open in 2nd Quarter of 2016By Nasdaq OMXJan 21, 2016, 5:48 PM UTC
BusinessHemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)By Nasdaq OMXJan 20, 2016, 1:30 PM UTC
BusinessEarth Science Tech Announces 20% Off Pre-Sale Campaign for its Revolutionary Health and Wellness “Advanced Stacking Systems” which Includes its Innovative Scientifically Formulated Bioceuticals and High Grade Hemp CBD (Cannabidiol) OilBy Nasdaq OMXJan 15, 2016, 2:09 PM UTC
BusinessEarth Science Tech Completes New Scientific Formulation of its All Natural Bioceutical Line and Introduces Cutting-Edge Advanced Hemp CBD (Cannabidiol) Stacking Systems for Health and Well-BeingBy Nasdaq OMXJan 7, 2016, 1:00 PM UTC
